marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-07-2024
Aclaris Therapeutics Balance Sheet 2011-2024 | ACRS
Annual Balance Sheet Aclaris Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36.4 M | -43 M | -24.5 M | -10.8 M | -35.3 M | -26.5 M | -20.1 M | -30.2 M | -9.85 M | -10.8 M | -9.59 M | - | - |
Long Term Debt |
3.07 M | 1.57 M | 2.15 M | 10.7 M | - | 29.9 M | - | - | - | - | - | - | - |
Long Term Debt Current |
426 K | 684 K | 693 K | 603 K | 526 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.95 M | 33.1 M | 5.48 M | 372 K | - | 36.7 M | 23 M | - | - |
Total Current Liabilities |
31 M | 21.9 M | 22.9 M | 14.9 M | 22.4 M | 27.3 M | 12.8 M | 6.22 M | 1.56 M | - | - | - | - |
Total Liabilities |
40.2 M | 57 M | 53.9 M | 33.1 M | 28.4 M | 60.4 M | 18.2 M | 6.6 M | 1.56 M | 38.1 M | 23.4 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-771 M | -682 M | -595 M | -505 M | -454 M | -292 M | -159 M | -90.9 M | -42.8 M | -20.7 M | -9.17 M | - | - |
Total Assets |
197 M | 255 M | 251 M | 70.8 M | 98.3 M | 276 M | 244 M | 176 M | 94.1 M | 17.4 M | 14.2 M | - | - |
Cash and Cash Equivalents |
39.9 M | 45.3 M | 27.3 M | 22.1 M | 35.9 M | 57 M | 20.2 M | 30.2 M | 9.85 M | 10.8 M | 9.59 M | - | - |
Book Value |
157 M | 198 M | 197 M | 37.6 M | 69.9 M | 215 M | 225 M | 169 M | 92.5 M | -20.8 M | -9.16 M | - | - |
Total Shareholders Equity |
157 M | 198 M | 197 M | 37.6 M | 69.9 M | 215 M | 225 M | 169 M | 92.5 M | -20.8 M | -9.16 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aclaris Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.37 M | 2.97 M | 3.07 M | 1.83 M | 1.9 M | 1.97 M | 1.57 M | 1.62 M | - | 2.02 M | 2.15 M | 2.38 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 3.55 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 295 K | 284 K | 372 K | 358 K | 345 K | 372 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
27.2 M | 32.1 M | 40.2 M | 62 M | 55.9 M | 52.9 M | 57 M | 47.8 M | - | 46.3 M | 53.9 M | 46.9 M | 54.2 M | 49.1 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 28.4 M | 28.4 M | 28.4 M | 28.4 M | 60.4 M | 60.4 M | 60.4 M | 60.4 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 1.56 M | 1.56 M | 1.56 M | 1.56 M | 1.46 M | 1.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-799 M | -788 M | -771 M | -769 M | -740 M | -710 M | -682 M | -655 M | - | -614 M | -595 M | -573 M | -551 M | -533 M | -505 M | -505 M | -505 M | -505 M | -454 M | -454 M | -454 M | -454 M | -292 M | -292 M | -292 M | -292 M | -159 M | -159 M | -159 M | -159 M | -90.9 M | -90.9 M | -90.9 M | -90.9 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -20.7 M | -20.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
161 M | 174 M | 197 M | 218 M | 236 M | 230 M | 255 M | 268 M | - | 227 M | 251 M | 263 M | 288 M | 161 M | 70.8 M | 70.8 M | 70.8 M | 70.8 M | 98.3 M | 98.3 M | 98.3 M | 98.3 M | 276 M | 276 M | 276 M | 276 M | 244 M | 244 M | 244 M | 244 M | 176 M | 176 M | 176 M | 176 M | 94.1 M | 94.1 M | 94.1 M | 94.1 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
22.8 M | 35.8 M | 39.9 M | 39 M | 31.2 M | 44.7 M | 45.3 M | 61.7 M | 68.3 M | 36.3 M | 27.3 M | 53.6 M | 113 M | 35.3 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 34.2 M | 34.2 M | 35.9 M | 35.9 M | 57 M | 57 M | 57 M | 54.9 M | 20.2 M | 60.1 M | 32.7 M | 23.7 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 9.85 M | 9.85 M | 9.85 M | 9.85 M | 10.8 M | 10.8 M | - | - | 9.59 M | - | - | - | 19 M | - | - | - | - | - | - | - |
Book Value |
134 M | 142 M | 157 M | 156 M | 180 M | 177 M | 198 M | 220 M | - | 180 M | 197 M | 217 M | 234 M | 112 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 215 M | 215 M | 215 M | 215 M | 225 M | 225 M | 225 M | 225 M | 169 M | 169 M | 169 M | 169 M | 92.5 M | 92.5 M | 92.5 M | 92.5 M | 15.9 M | 15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
134 M | 142 M | 157 M | 156 M | 180 M | 177 M | 198 M | 220 M | 236 M | 180 M | 197 M | 217 M | 234 M | 112 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 215 M | 215 M | 215 M | 215 M | 225 M | 225 M | 225 M | 225 M | 169 M | 169 M | 169 M | 169 M | 92.5 M | 92.5 M | 92.5 M | 92.5 M | -20.8 M | -20.8 M | - | - | -9.16 M | - | - | - | -2.19 M | - | - | - | - | - | - | - |
All numbers in USD currency